SCHEMBL25822741

SCHEMBL25822741

Cn1cc(-c2ccc3nc(Nc4ccc(N5CCC(C)(O)CC5)cc4)c4nccn4c3c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 9/20 0.51
LRRK2 Q5S007 1/20 0.45
MAPKAPK5 Q8IW41 5/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ERBB4 Q15303 1/20 0.40
AURKA O14965 1/20 0.39
FYN P06241 1/20 0.39
JUN P05412 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
CD63 P08962 2/20 0.38
IKBKB O14920 1/20 0.38
JAK2 O60674 1/20 0.38
NTRK1 P04629 1/20 0.38
ROS1 P08922 1/20 0.38
CSNK2A2 P19784 1/20 0.38
FLT3 P36888 1/20 0.38
CSNK2B P67870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822739 0.87 MAPKAPK5 (0.49) LRRK2MAPKAPK5EGFR
SCHEMBL25822687 0.86 SYK (0.54) SYKMAPKAPK5AURKAJAK2NTRK1
SCHEMBL25822743 0.83 SYK (0.48) SYKMAPKAPK5EGFRFYNCD63
SCHEMBL25822767 0.78 SYK (0.38) SYKMAPKAPK5AURKAFYNCD63
SCHEMBL25822683 0.76 MAPKAPK5 (0.54) SYKLRRK2MAPKAPK5EGFRAURKA
SCHEMBL25822696 0.76 MAPKAPK5 (0.56) SYKMAPKAPK5AURKAFYNJUN
SCHEMBL25823182 0.76 SYK (0.49) SYKMAPKAPK5AURKAFYNMAPK10
SCHEMBL26184431 0.74 MAPT (0.54) SYKMAPKAPK5FYNMAPK8
SCHEMBL2481066 0.74 SYK (0.67) SYKAURKACD63JAK2NTRK1
SCHEMBL25822763 0.74 MAPT (0.46) SYKMAPKAPK5AURKAFYNCD63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 SYK 1/4885LRRK2 743/4885MAPKAPK5 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.